Medical Cannabis Milestone? Khiron Opens Clinic in London

Medical Cannabis Milestone? Khiron Opens Clinic in London

Courtesy of Pexels

The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga.

Khiron Life Sciences Corp. KHRN KHRNF says it is on a mission to conquer the medical cannabis market in Europe with the opening of Zerenia Clinics UK in London as the company’s first International Zerenia clinic on the continent.

The move brings Khiron’s total clinic count to 15 globally and may strengthen the company’s European sales, which now account for 30% of its total medical cannabis revenue for the 3rd quarter of 2021.

Zerenia Clinics UK hopes to build on Khiron’s presence in the UK, which started in 2019 when the company became a founding member and exclusive Latin American supplier for Project Twenty21, which offers a subsidized pricing model for patients in the program to address barriers to access the market.

“I am very excited about the opening of Zerenia Clinics UK in London with our very experienced local team,” Khiron Europe President Franziska Katterbach said. “This is a great milestone for Khiron and will contribute significantly to the dynamics of developing a market for medical cannabis in the UK. From day one, it has been our goal to improve patient access to medical cannabis where suitable and also create evidence for the effectiveness and tolerability of medical cannabis; opening a UK cannabis clinic is just another logical step to serve patients’ and clinicians’ needs.”

Initially, Zerenia Clinics UK will focus on pain management before expanding its therapeutic portfolio to other areas such as mental health, women’s health, neurology, and oncology. The clinic is located in London’s Chelsea district but will initially focus on supporting patients digitally or via video consultations to streamline access. 

Is the Medical Cannabis Market in the UK on Track for Rapid Growth?

The London clinic expands Khiron’s presence in Europe, where medical cannabis sales have grown more than 6 times since the 1st quarter. While Germany is projected by some to continue to dominate the European medical cannabis market until at least 2024, the UK medical cannabis market is expected to show the most significant growth of any country on the continent by 2025, according to Prohibition Partners, a London-based market intelligence firm serving the global cannabis industry.

Khiron Life Sciences is a leading vertically integrated global medical cannabis company with core operations in Latin America and Europe. The company is licensed in Colombia for cultivation, production, domestic distribution, and international export of both low- and high-THC medical cannabis products from Colombia to the UK.

The preceding post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Although the piece is not and should not be construed as editorial content, the sponsored content team works to ensure that any and all information contained within is true and accurate to the best of their knowledge and research. This content is for informational purposes only and not intended to be investing advice.

Posted In: Khiron Life Sciences Corp.Partner ContentCannabisPenny StocksMarkets

BENZINGA CANNABIS CONFERENCE

Meet the biggest cannabis industry players and make deals that will push the industry forward.

Featuring live company presentations, insider panels, and unmatched access to networking, the Benzinga Cannabis Capital Conference is where cannabis executives and entrepreneurs meet.

Join us April 11-12, 2023 at Fontainebleau Miami Beach in sunny Florida.